Worthington has been the Chief Operating Officer of Chan Zuckerberg Biohub since May of 2017. As COO, he has worked with the co-presidents to set strategy and objectives for CZ Biohub and has built and overseen much of the organization. This includes recruiting the finance, legal, IT, and HR teams; executive leadership; and the chief scientific officer. Over the years, Worthington has assisted in the formation of and advised dozens of startups, and has worked to foster an entrepreneurial spirit at CZ Biohub.
From early 1999 to October 2016, Worthington was the chief executive officer of Fluidigm Corporation (NASDAQ: FLDM), a company he co-founded. During his tenure at Fluidigm, he led the development and commercialization of Fluidigm’s technology, resulting in revenues of approximately $120M from multiple product lines. Along the way, Fluidigm became a recognized leader in microfluidics, pioneered the single-cell genomics market, raised over $500M in private and public funding, acquired the CYTOF technology through the acquisition of DVS Sciences, and ultimately employed over 600 people globally, with operations in the U.S., France, the UK, Japan, Singapore, and China.
Worthington earned a B.S. in physics and an MSEE from Stanford University. He served on the advisory board for Stanford’s Technology Ventures Program from 2001 to 2006. He is also an elected fellow of the American Institute for Medical and Biological Engineering (AIMBE).